Aravive is now enrolling patients in the AXLerate Phase 3 trial of AVB-500 in platinum-resistant ovarian cancer.


Aravive is excited to join the Foundation for Women’s Cancer Move4Her event on September 26, 2021. A live one-hour, fully virtual and interactive exercise event to raise crucial funds for awareness, education, outreach and research of gynecologic cancers – We hope to see you there!


Aravive was founded with the mission to develop novel therapeutics to improve the health and extend the lives of patients with cancer and fibrotic diseases.

Our science is driven by an understanding of the central role played by GAS6/AXL signaling in cell migration and invasion. Our drug candidates are designed to block this pathway by intercepting the binding of AXL to its sole ligand, GAS6, by means of a novel ultra-high affinity AXL decoy receptor, AVB-500.